Mannose receptor-mediated delivery of moss-made α-galactosidase A efficiently corrects enzyme deficiency in Fabry mice

Journal of Inherited Metabolic Disease

Volumn 39, Issue 2, 2016, Pages 293-303

  Shen, Jin Song ^a   Busch, Andreas ^b   Day, Taniqua S ^a   Meng, Xing Li ^a   Yu, Chun I ^c   Dabrowska Schlepp, Paulina ^b   Fode, Benjamin ^b   Niederkrüger, Holger ^b   Forni, Sabrina ^a   Chen, Shuyuan ^d   Schiffmann, Raphael ^a   Frischmuth, Thomas ^b   Schaaf, Andreas ^b  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b Greenovation Biotech GmbH   (Germany)

^c BAYLOR INSTITUTE FOR IMMUNOLOGY RESEARCH   (United States)

^d BAYLOR RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGALSIDASE ALFA; ALPHA GALACTOSIDASE; CARBOHYDRATE; MANNAN; MANNOSE; MANNOSE RECEPTOR; CELL SURFACE RECEPTOR; ISOENZYME; LECTIN; MANNOSE BINDING LECTIN; MANNOSE PHOSPHATE; MANNOSE-6-PHOSPHATE; SOMATOMEDIN B RECEPTOR;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAPILLARY ENDOTHELIAL CELL; CARBOHYDRATE ANALYSIS; CELLULAR DISTRIBUTION; COMPARATIVE STUDY; CONTROLLED STUDY; ENDOCYTOSIS; ENZYME ACTIVITY; ENZYME DEFICIENCY; ENZYME DEGRADATION; ENZYME INACTIVATION; ENZYME PURIFICATION; FABRY DISEASE; FEMALE; HEATING; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MOSS; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN DEGRADATION; SIZE EXCLUSION CHROMATOGRAPHY; ANIMAL; C57BL MOUSE; CELL LINE; DISEASE MODEL; ENZYME REPLACEMENT; ENZYMOLOGY; HUMAN; KIDNEY; LYSOSOME STORAGE DISEASE; MALE; METABOLISM; PROCEDURES;

ALPHA-GALACTOSIDASE; ANIMALS; CELL LINE; DISEASE MODELS, ANIMAL; ENZYME REPLACEMENT THERAPY; FABRY DISEASE; FEMALE; HUMANS; ISOENZYMES; KIDNEY; LECTINS, C-TYPE; LYSOSOMAL STORAGE DISEASES; MALE; MANNOSE-BINDING LECTINS; MANNOSEPHOSPHATES; MICE; MICE, INBRED C57BL; RECEPTOR, IGF TYPE 2; RECEPTORS, CELL SURFACE;

EID: 84958177713     PISSN: 01418955     EISSN: 15732665     Source Type: Journal    
DOI: 10.1007/s10545-015-9886-9     Document Type: Article

References (43)

1. Ashe KM, Budman E, Bangari DS, et al (2015) Efficacy of enzyme and substrate reduction therapy with a novel antagonist of glucosylceramide synthase for Fabry disease. Mol Med
2. Ballou CE (1990) Isolation, characterization, and properties of Saccharomyces cerevisiae mnn mutants with nonconditional protein glycosylation defects. Methods Enzymol 185:440–470
3. Barton NW, Brady RO, Dambrosia JM et al (1991) Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher’s disease. N Engl J Med 324:1464–1470
4. Bonten EJ, Wang D, Toy JN et al (2004) Targeting macrophages with baculovirus-produced lysosomal enzymes: implications for enzyme replacement therapy of the glycoprotein storage disorder galactosialidosis. FASEB J 18:971–973
5. Brady R, Gal AE, Bradley RM, Martensson E, Warshaw AL, Laster L (1967) Enzymatic defect in Fabry disease: ceramide trihexosidase deficiency. N Engl J Med 276:1163–1167
6. Chen Y, Jin M, Egborge T, Coppola G, Andre J, Calhoun DH (2000a) Expression and characterization of glycosylated and catalytically active recombinant human alpha-galactosidase A produced in Pichia pastoris. Protein Expr Purif 20:472–484
7. Chen Y, Jin M, Goodrich L, Smith G, Coppola G, Calhoun DH (2000b) Purification and characterization of human alpha-galactosidase A expressed in insect cells using a baculovirus vector. Protein Expr Purif 20:228–236
8. Chiba Y, Sakuraba H, Kotani M et al (2002) Production in yeast of alpha-galactosidase A, a lysosomal enzyme applicable to enzyme replacement therapy for Fabry disease. Glycobiology 12:821–828
9. Christensen EI, Zhou Q, Sorensen SS et al (2007) Distribution of alpha-galactosidase A in normal human kidney and renal accumulation and distribution of recombinant alpha-galactosidase A in Fabry mice. J Am Soc Nephrol 18:698–706
10. Costa AR, Rodrigues ME, Henriques M, Oliveira R, Azeredo J (2014) Glycosylation: impact, control and improvement during therapeutic protein production. Crit Rev Biotechnol 34:281–299
11. Deegan PB (2012) Fabry disease, enzyme replacement therapy and the significance of antibody responses. J Inherit Metab Dis 35:227–243
12. Desnick RJ, Ioannou YA, Eng CM (2001) α-Galactosidase A deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease. McGraw-Hill, New York, pp 3733–3774
13. Du H, Cameron TL, Garger SJ et al (2008) Wolman disease/cholesteryl ester storage disease: efficacy of plant-produced human lysosomal acid lipase in mice. J Lipid Res 49:1646–1657
14. Durant B, Forni S, Sweetman L et al (2011) Sex differences of urinary and kidney globotriaosylceramide and lyso-globotriaosylceramide in Fabry mice. J Lipid Res 52:1742–1746
15. Eng CM, Banikazemi M, Gordon RE et al (2001a) A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet 68:711–722
16. Eng CM, Guffon N, Wilcox WR et al (2001b) Safety and efficacy of recombinant human alpha-galactosidase A—replacement therapy in Fabry’s disease. N Engl J Med 345:9–16
17. Gomord V, Faye L (2004) Posttranslational modification of therapeutic proteins in plants. Curr Opin Plant Biol 7:171–181
18. Groger M, Holnthoner W, Maurer D et al (2000) Dermal microvascular endothelial cells express the 180-kDa macrophage mannose receptor in situ and in vitro. J Immunol 165:5428–5434
19. He X, Haselhorst T, von Itzstein M et al (2012) Production of alpha-L-iduronidase in maize for the potential treatment of a human lysosomal storage disease. Nat Commun 3:1062
20. Ioannou YA, Zeidner KM, Gordon RE, Desnick RJ (2001) Fabry disease: preclinical studies demonstrate the effectiveness of alpha-galactosidase A replacement in enzyme-deficient mice. Am J Hum Genet 68:14–25
21. Kizhner T, Azulay Y, Hainrichson M et al (2015) Characterization of a chemically modified plant cell culture expressed human alpha-Galactosidase-A enzyme for treatment of Fabry disease. Mol Genet Metab 114:259–267
22. Koprivova A, Stemmer C, Altmann F et al (2004) Targeted knockouts of Physcomitrella lacking plant-specific immunogenic N-glycans. Plant Biotechnol J 2:517–523
23. Kornfeld S (1992) Structure and function of the mannose 6-phosphate/insulinlike growth factor II receptors. Annu Rev Biochem 61:307–330
24. Lee K, Jin X, Zhang K et al (2003) A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease. Glycobiology 13:305–313
25. Linehan SA, Martinez-Pomares L, Stahl PD, Gordon S (1999) Mannose receptor and its putative ligands in normal murine lymphoid and nonlymphoid organs: In situ expression of mannose receptor by selected macrophages, endothelial cells, perivascular microglia, and mesangial cells, but not dendritic cells. J Exp Med 189:1961–1972
26. Marchesan D, Cox TM, Deegan PB (2012) Lysosomal delivery of therapeutic enzymes in cell models of Fabry disease. J Inherit Metab Dis 35:1107–1117
27. Murray GJ, Anver MR, Kennedy MA, Quirk JM, Schiffmann R (2007) Cellular and tissue distribution of intravenously administered agalsidase alfa. Mol Genet Metab 90:307–312
28. Ohshima T, Murray GJ, Swaim WD et al (1997) alpha-Galactosidase A deficient mice: a model of Fabry disease. Proc Natl Acad Sci U S A 94:2540–2544
29. Pastores GM (2007) Agalsidase alfa (Replagal) in the treatment of Anderson-Fabry disease. Biogeosciences 1:291–300
30. Prabakaran T, Nielsen R, Larsen JV et al (2011) Receptor-mediated endocytosis of alpha-galactosidase A in human podocytes in Fabry disease. PLoS One 6, e25065
31. Prabakaran T, Nielsen R, Satchell SC et al (2012) Mannose 6-phosphate receptor and sortilin mediated endocytosis of alpha-galactosidase A in kidney endothelial cells. PLoS One 7, e39975
32. Sands MS, Vogler CA, Ohlemiller KK et al (2001) Biodistribution, kinetics, and efficacy of highly phosphorylated and non-phosphorylated beta-glucuronidase in the murine model of mucopolysaccharidosis VII. J Biol Chem 276:43160–43165
33. Schiffmann R, Murray GJ, Treco D et al (2000) Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. Proc Natl Acad Sci U S A 97:365–370
34. Schiffmann R, Kopp JB, Austin HA 3rd et al (2001) Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 285:2743–2749
35. Shaaltiel Y, Bartfeld D, Hashmueli S et al (2007) Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher’s disease using a plant cell system. Plant Biotechnol J 5:579–590
36. Shen JS, Meng XL, Schiffmann R, Brady RO, Kaneski CR (2007) Establishment and characterization of Fabry disease endothelial cells with an extended lifespan. Mol Genet Metab 92:137–144
37. Shen JS, Meng XL, Wight-Carter M et al (2015) Blocking hyperactive androgen receptor signaling ameliorates cardiac and renal hypertrophy in Fabry mice. Hum Mol Genet 24:3181–3191
38. Sly WS, Vogler C, Grubb JH et al (2006) Enzyme therapy in mannose receptor-null mucopolysaccharidosis VII mice defines roles for the mannose 6-phosphate and mannose receptors. Proc Natl Acad Sci U S A 103:15172–15177
39. Stahl PD, Ezekowitz RA (1998) The mannose receptor is a pattern recognition receptor involved in host defense. Curr Opin Immunol 10:50–55
40. Tsukimura T, Kawashima I, Togawa T et al (2012) Efficient uptake of recombinant alpha-galactosidase A produced with a gene-manipulated yeast by Fabry mice kidneys. Mol Med 18:76–82
41. Van Patten SM, Hughes H, Huff MR et al (2007) Effect of mannose chain length on targeting of glucocerebrosidase for enzyme replacement therapy of Gaucher disease. Glycobiology 17:467–478
42. Zhu Y, Jiang JL, Gumlaw NK et al (2009) Glycoengineered acid alpha-glucosidase with improved efficacy at correcting the metabolic aberrations and motor function deficits in a mouse model of Pompe disease. Mol Ther 17:954–963
43. Ziegler RJ, Cherry M, Barbon CM et al (2007) Correction of the biochemical and functional deficits in fabry mice following AAV8-mediated hepatic expression of alpha-galactosidase A. Mol Ther 15:492–500